Click here to close now.




















Welcome!

News Feed Item

Immunotec Announces 2013 Fourth Quarter and Full Year Financial Results

Best results since going public in 2007 (Revenues achieving a record $54.8M and Net Profit reaching $1.4M)

VAUDREUIL-DORION, QUEBEC -- (Marketwired) -- 02/13/14 -- Immunotec Inc. (TSX VENTURE: IMM), a Canadian based company and a leader in the wellness industry (the "Company") today released its fourth quarter and full year results for the period ended 31 October 2013.

The Company, led by its consultants and employees, made significant progress as shown in its performance against key metrics" said Mr. Charles L. Orr, Immunotec's Chief Executive Officer. "We are grateful for how all our stakeholders are collaborating to support Immunotec's vision to become the company of choice for nutrition and lifestyle improvement".

"The 2013 Financial Results are the strongest since the Company became public in 2007", said Mr. Patrick Montpetit, Immunotec's Chief Financial Officer. "We are pleased with the trend of financial results over the last eight quarters and the potential for the quarters ahead".

2013 and Subsequent Year-End Highlights:


--  Total revenues reached $54.8M, an increase of 11.3% as compared to the
    previous year.

--  Network sales reached $49.6M, an increase of 12.2% as compared to the
    previous year.

--  Selected expenses(1), defined as administrative, marketing and selling,
    and quality and development expenses amounted to $11.9M and measured
    favourably as a percentage of total revenues by improving to 21.7% as
    compared to 24.0% in the previous year.

--  Adjusted EBITDA(1), amounted to $2.9M or 5.2% of total revenues,
    compared to $1.9M or 3.8% of total revenues in the previous year.

--  Net profit of $1.4M, compared to $0.1M in the previous year.

--  Total basic and fully diluted profit per common share was $0.02.

--  The Company repurchased a total of 732,000 shares under the Normal
    Course Issuer Bid ("NCIB") program.

For the year ended 31 October 2013, Immunotec recorded Network sales of $49.6M as compared to $44.2M for the previous year, an increase of 12.2% or $5.4M. This increase was driven by a $4.8M gain over the previous year from the Mexican operations. Other revenue, which includes revenues of products sold to licensees, freight and shipping and educational material purchased by our network of independent consultants, was stable at $5.1M compared to $5.0M in the previous year.

Sales incentives paid to our Network is the Company's most significant expense and consists of commissions, performance bonuses and other promotional incentives provided to qualifying consultants. During the year ended 31 October 2013, the Company incurred $25.8M in Sales incentives paid to our Network for an average of 51.9% of total Network sales compared to 51.1% of total Network sales in the previous year.

Selected expenses(1) in year ended 31 October 2013 amounted to $11.9M as compared to $11.8M for the previous year. As a result of the growth in revenues in 2013 being achieved without a commensurate growth in these expenses, their percentage of total revenues improved to 21.7% as compared to 24.0% in the previous year.

For the year ended 31 October 2013, adjusted EBITDA(1) was $2.9M or 5.2% of revenues, versus $1.9M or 3.8% for the previous year. Adjusted EBITDA has improved 53.0% over the previous year while revenue increased 11.3% reflecting a disciplined approach to expense management.

Net profit for the year ended 31 October 2013 totalled $1.4M, as compared to net profit of $0.1M for the previous year. This year-over-year improvement is primarily the result of revenue growth in Mexico. Total basic and fully diluted profit per common share for the year ended 31 October 2013 was $0.02, compared to $0.00 in the previous year.

During the year, under the Normal Course Issuer Bid (NCIB) program, the Company repurchased and cancelled 732,000 common shares for cash consideration of $0.2M, whereas repurchases made in the corresponding period in the previous year were not significant.

Subsequent to the year ended 31 October 2013, the Company amended the terms and conditions of its existing credit facilities with the lender. An additional tranche of up to approximately $0.25M was added to the existing Committed Reducing Term Facility, bearing interest at 3.63%, and maturing in September 2016. This amount was received in January 2014. A new Committed Reducing Term Facility in the amount of $0.5M, bearing interest at 4.34% and maturing in February 2017 was added. Certain additional collateralization was included in the agreement, including cross-guarantees from Group companies. The entire $0.5M amount was drawn in February 2014.

Pursuant to the Immunotec Stock Option Plan, on 17 February 2014, a director will be granted 25,000 options to acquire up to an aggregate of 25,000 common shares (the "Shares"). The exercise price of such options will be established at the closing trading price on that day. These options will vest over a three-year period, with one-third (1/3) which will vest on each of the first, second and third anniversaries of the date of the grant. Each option is exercisable, once vested, for a period of five years from the date of the grant.

Financial Results for the Fourth Quarter of 2013

In the three-month period ended 31 October 2013, total revenue reached $15.5M, an increase of 13.1% as compared to the same period in the previous year when total revenues were $13.7M. Of this amount, Network sales comprised $14.2M or 91.6% of total sales, as compared to 89.8% in the same period in the previous year when Network sales were $12.3M. The fourth quarter increase is due primarily to sales growth in Mexico and the Western United States.

Selected expenses(1) as a percentage of total revenues were 16.1% in the three- month period ended 31 October 2013, as compared to 21.2% of total revenues for the same quarter in the previous year. This improvement in the fourth quarter is due primarily to improved administrative costs and the recognition of research and development tax credits in Canada.

The net profit in the three-month period ended 31 October 2013 was $0.4M, compared to a loss of $0.1M in the same period in the previous year.

About Immunotec Inc.

Immunotec Inc. is dedicated to making a positive difference in people's lifestyle every day by offering research-driven nutritional products through its network of Independent Consultants worldwide. Immunotec's strength comes from its culture that emphasizes teamwork and entrepreneurial leadership by employees, consultants and research collaborators.

Headquartered with manufacturing facilities near Montreal, Canada, Immunotec Consultants generate nearly $55.0 Million in annual revenues. Please visit us at www.immunotec.com for additional information.

The Company files its consolidated financial statements, its management and discussion analysis report, its press releases and such other required documents on the SEDAR database at www.sedar.com and on the Company's website at www.immunotec.com. The common shares of the Company are listed on the TSX Venture Exchange under the ticker symbol IMM. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS: Certain statements contained in this news release are forward looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Immunotec's most recent Management's Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.

Selected Financial Information

The following tables summarize selected financial information from the Consolidated Statements of Income and the Consolidated Statements of Financial Position regarding the Company's results of operations and financial position.


                       Selected Financial Information


For the years ended 31 October
('000s of C$, except for share and per share
 data)                                                  2013           2012
----------------------------------------------------------------------------

Revenues                                              54,771         49,206
Cost of goods sold                                     9,989          8,858
Sales incentives - Network                            25,786         22,616
Other variable costs                                   4,505          4,260
----------------------------------------------------------------------------
Margin before expenses                                14,491         13,472
Expenses                                              13,456         13,261
----------------------------------------------------------------------------
Operating income                                       1,035            211
Net finance (income) expenses                            (64)            85
Income taxes (recovery)                                 (278)             1
----------------------------------------------------------------------------
Net profit                                             1,377            125
----------------------------------------------------------------------------
Total comprehensive income (loss)                      1,293             (2)

Net profit per share:
Basic and diluted                                       0.02           0.00
Weighted average common shares oustanding:
Basic and diluted                                 69,600,040     69,985,287
----------------------------------------------------------------------------


As at                                             31 October     31 October
(000's of C$)                                           2013           2012
----------------------------------------------------------------------------
Cash (net of bank indebtedness)                        4,706          3,774
Total assets                                          23,495         19,932
Long- term liabilities (including current
 portions)                                             2,021          2,081
Equity                                                13,071         11,972
----------------------------------------------------------------------------



                     Geographic distribution of revenues

For the year ended 31 October
('000s of C$)                                           2013           2012
----------------------------------------------------------------------------

Mexico                                                24,064         18,268
Canada                                                13,897         15,055
United States                                         14,057         13,444
Other countries                                        2,753          2,439
----------------------------------------------------------------------------
                                                      54,771         49,206
----------------------------------------------------------------------------



           Selected expenses as a percentage (%) of total revenue

For the year ended 31 October
('000s of C$)                                2013       %      2012       %
----------------------------------------------------------------------------

Revenues                                   54,771   100.0%   49,206   100.0%
Selected expenses
Administrative                              6,072    11.1%    5,964    12.1%
Marketing and selling                       5,227     9.5%    4,974    10.1%
Quality and development costs                 603     1.1%      891     1.8%
----------------------------------------------------------------------------
                                           11,902    21.7%   11,829    24.0%
----------------------------------------------------------------------------



                       Calculation of adjusted EBITDA

For the year ended 31 October
('000s of C$)                                                 2013     2012
----------------------------------------------------------------------------

Net profit                                                   1,377      125

Add (deduct):
  Depreciation and amortization                                814      946
  Net finance (income) expenses                                (64)      85
  Administrative assessments from a foreign jurisdiction       282      233
  Other expenses                                               740      487
  Income tax (recovery) expense                               (278)       1
----------------------------------------------------------------------------
Adjusted EBITDA                                              2,871    1,877
----------------------------------------------------------------------------

Percentage of revenues                                         5.2%     3.8%
----------------------------------------------------------------------------

(1) Adjusted EBITDA and Selected Expenses are a non-GAAP measures providing additional information on the commercial performance of regular operations. Adjusted EBITDA corresponds to EBITDA as defined Earnings before Interest Taxes Depreciation and Amortization less elements that management considers outside of the normal activities of the Company. Selected Expenses correspond to general administration charges and fixed overhead charges in the normal activities of the Company. For more information please refer to the non-GAAP measures section of the most recent Management Discussion and Analysis filed on www.sedar.com.

Contacts:
Patrick Montpetit CPA, CA, CF
Vice-President and Chief Financial Officer,
Immunotec Inc.
(450) 510-4527

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
SYS-CON Events announced today that Pythian, a global IT services company specializing in helping companies leverage disruptive technologies to optimize revenue-generating systems, has been named “Bronze Sponsor” of SYS-CON's 17th Cloud Expo, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Founded in 1997, Pythian is a global IT services company that helps companies compete by adopting disruptive technologies such as cloud, Big Data, advance...
Skeuomorphism usually means retaining existing design cues in something new that doesn’t actually need them. However, the concept of skeuomorphism can be thought of as relating more broadly to applying existing patterns to new technologies that, in fact, cry out for new approaches. In his session at DevOps Summit, Gordon Haff, Senior Cloud Strategy Marketing and Evangelism Manager at Red Hat, discussed why containers should be paired with new architectural practices such as microservices rathe...
IBM’s Blue Box Cloud, powered by OpenStack, is now available in any of IBM’s globally integrated cloud data centers running SoftLayer infrastructure. Less than 90 days after its acquisition of Blue Box, IBM has integrated its Blue Box Cloud Dedicated private-cloud-as-a-service into its broader portfolio of OpenStack® based solutions. The announcement, made today at the OpenStack Silicon Valley event, further highlights IBM’s continued support to deliver OpenStack solutions across all cloud depl...
ElasticBox, the agile application delivery manager, announced freely available public boxes for the DevOps community. ElasticBox works with enterprises to help them deploy any application to any cloud. Public boxes are curated reference boxes that represent some of the most popular applications and tools for orchestrating deployments at scale. Boxes are an adaptive way to represent reusable infrastructure as components of code. Boxes contain scripts, variables, and metadata to automate proces...
Puppet Labs is pleased to share the findings from our 2015 State of DevOps Survey. We have deepened our understanding of how DevOps enables IT performance and organizational performance, based on responses from more than 20,000 technical professionals we’ve surveyed over the past four years. The 2015 State of DevOps Report reveals high-performing IT organizations deploy 30x more frequently with 200x shorter lead times. They have 60x fewer failures and recover 168x faster
To support developers and operations professionals in their push to implement DevOps principles for their infrastructure environments, ProfitBricks, a provider of cloud infrastructure, is adding support for DevOps tools Ansible and Chef. Ansible is a platform for configuring and managing data center infrastructure that combines multi-node software deployment, ad hoc task execution, and configuration management, and is used by DevOps professionals as they use its playbooks functionality to autom...
SYS-CON Events announced today that IceWarp will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. IceWarp, the leader of cloud and on-premise messaging, delivers secured email, chat, documents, conferencing and collaboration to today's mobile workforce, all in one unified interface
Containers are not new, but renewed commitments to performance, flexibility, and agility have propelled them to the top of the agenda today. By working without the need for virtualization and its overhead, containers are seen as the perfect way to deploy apps and services across multiple clouds. Containers can handle anything from file types to operating systems and services, including microservices. What are microservices? Unlike what the name implies, microservices are not necessarily small,...
All major researchers estimate there will be tens of billions devices - computers, smartphones, tablets, and sensors - connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo, November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Learn what is going on, contribute to the discussions, and e...
This Enterprise Strategy Group lab validation report of the NEC Express5800/R320 server with Intel® Xeon® processor presents the benefits of 99.999% uptime NEC fault-tolerant servers that lower overall virtualized server total cost of ownership. This report also includes survey data on the significant costs associated with system outages impacting enterprise and web applications. Click Here to Download Report Now!
It’s been proven time and time again that in tech, diversity drives greater innovation, better team productivity and greater profits and market share. So what can we do in our DevOps teams to embrace diversity and help transform the culture of development and operations into a true “DevOps” team? In her session at DevOps Summit, Stefana Muller, Director, Product Management – Continuous Delivery at CA Technologies, answered that question citing examples, showing how to create opportunities for ...
SYS-CON Events announced today that G2G3 will exhibit at SYS-CON's @DevOpsSummit Silicon Valley, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Based on a collective appreciation for user experience, design, and technology, G2G3 is uniquely qualified and motivated to redefine how organizations and people engage in an increasingly digital world.
Too often with compelling new technologies market participants become overly enamored with that attractiveness of the technology and neglect underlying business drivers. This tendency, what some call the “newest shiny object syndrome,” is understandable given that virtually all of us are heavily engaged in technology. But it is also mistaken. Without concrete business cases driving its deployment, IoT, like many other technologies before it, will fade into obscurity.
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, will discuss how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a prac...
The 3rd International WebRTC Summit, to be held Nov. 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA, announces that its Call for Papers is now open. Topics include all aspects of improving IT delivery by eliminating waste through automated business models leveraging cloud technologies. WebRTC Summit is co-located with 15th International Cloud Expo, 6th International Big Data Expo, 3rd International DevOps Summit and 2nd Internet of @ThingsExpo. WebRTC (Web-based Real-Time Com...